Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
SpringsWorks Therapeutics completes enrollment of Phase 3 DeFi trial » 06:35
07/22/20
07/22
06:35
07/22/20
06:35
SWTX

SpringsWorks Therapeutics

$37.61 /

-1.005 (-2.60%)

SpringWorks Therapeutics…

SpringWorks Therapeutics has achieved full enrollment in its Phase 3 DeFi trial evaluating nirogacestat, an investigational gamma secretase inhibitor, in adult patients with progressing desmoid tumors. SpringWorks expects to report topline results from the DeFi trial in Q2 or Q3 2021. The DeFi trial is a Phase 3 trial to evaluate the efficacy, safety and tolerability of nirogacestat in adult patients with progressing desmoid tumors. Patients have been randomized 1:1 to receive 150 mg of nirogacestat or placebo twice daily. The primary endpoint is progression-free survival and secondary endpoints include safety and tolerability measures, as well as objective response rate, changes in tumor volume assessed by MRI, and changes in patient-reported outcomes. Nirogacestat has received Orphan Drug Designation from the FDA for the treatment of desmoid tumors and from the European Commission for the treatment of soft tissue sarcoma. The FDA also granted Fast Track and Breakthrough Therapy Designations for the treatment of adult patients with progressive, unresectable, recurrent or refractory desmoid tumors or deep fibromatosis.

ShowHide Related Items >><<
SWTX SpringsWorks Therapeutics
$37.61 /

-1.005 (-2.60%)

SWTX SpringsWorks Therapeutics
$37.61 /

-1.005 (-2.60%)

06/02/20 Citi
Ayala Pharmaceuticals initiated with a Buy at Citi
05/05/20 Barclays
SpringsWorks Therapeutics initiated with an Overweight at Barclays
03/19/20 H.C. Wainwright
SpringsWorks Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
03/04/20
Fly Intel: Top five analyst downgrades
SWTX SpringsWorks Therapeutics
$37.61 /

-1.005 (-2.60%)

  • 13
    Sep
Over a month ago
Hot Stocks
BeiGene, SpringsWorks present preclincal data on lifirafenib with mirdametinib » 09:08
06/22/20
06/22
09:08
06/22/20
09:08
BGNE

BeiGene

$182.57 /

+5.09 (+2.87%)

, SWTX

SpringsWorks Therapeutics

$44.98 /

-3.53 (-7.28%)

BeiGene (BGNE) and…

BeiGene (BGNE) and SpringWorks Therapeutics (SWTX) announced the presentation of preclinical data and provided a program update on their ongoing Phase 1b/2 study evaluating the combination of BeiGene's investigational RAF dimer inhibitor, lifirafenib, with SpringWorks' investigational MEK inhibitor, mirdametinib, in patients with advanced or refractory solid tumors harboring mutations in the MAPK pathway, including those with RAS mutations. The preclinical data were presented in a poster at the American Association for Cancer Research 2020 Virtual Annual Meeting II by researchers from BeiGene, SpringWorks, and Memorial Sloan Kettering Cancer Center. Among the findings presented, lifirafenib and mirdametinib demonstrated potent and synergistic activity in vitro and in vivo across a panel of RAS-mutated cancer models harboring a variety of mutations using clinically relevant concentrations of the compounds. Furthermore, in KRAS Q61K and KRAS G12C xenograft models, the combination demonstrated synergy as validated by pharmacodynamic pathway inhibition and tumor regressions. These preclinical findings provided further support for the ongoing Phase 1b/2 combination study of lifirafenib and mirdametinib, which is evaluating this "vertical inhibition" strategy for treating patients whose cancers harbor RAS mutations and other MAPK pathway aberrations. Based on the progress of the program and the clinical data observed to date, the companies reiterated their previous guidance to complete the dose escalation portion of the trial by the end of 2020 and to commence dose expansion cohorts in tumor types of interest thereafter, including KRAS-mutated non-small cell lung cancer and KRAS-mutated endometrial cancer. Initial clinical data from the trial is expected to be presented at a medical conference in 2021.

ShowHide Related Items >><<
SWTX SpringsWorks Therapeutics
$44.98 /

-3.53 (-7.28%)

BGNE BeiGene
$182.57 /

+5.09 (+2.87%)

BGNE BeiGene
$182.57 /

+5.09 (+2.87%)

06/03/20 Piper Sandler
BeiGene earned 'meaningful' approvals for Brukinsa in China, says Piper Sandler
03/25/20 Piper Sandler
BeiGene Abraxane issue could take months to resolve, says Piper Sandler
03/13/20 Macquarie
BeiGene upgraded to Neutral from Underperform at Macquarie
03/03/20 Maxim
BeiGene price target lowered to $190 from $210 at Maxim
SWTX SpringsWorks Therapeutics
$44.98 /

-3.53 (-7.28%)

06/02/20 Citi
Ayala Pharmaceuticals initiated with a Buy at Citi
05/05/20 Barclays
SpringsWorks Therapeutics initiated with an Overweight at Barclays
03/19/20 H.C. Wainwright
SpringsWorks Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
03/04/20
Fly Intel: Top five analyst downgrades
SWTX SpringsWorks Therapeutics
$44.98 /

-3.53 (-7.28%)

BGNE BeiGene
$182.57 /

+5.09 (+2.87%)

BGNE BeiGene
$182.57 /

+5.09 (+2.87%)

Hot Stocks
SpringsWorks Therapeutics: Dosing begins in Phase 1b study of nirogacestat » 06:38
06/22/20
06/22
06:38
06/22/20
06:38
SWTX

SpringsWorks Therapeutics

$44.98 /

-3.53 (-7.28%)

, GSK

GlaxoSmithKline

$41.12 /

+0.18 (+0.44%)

SpringWorks Therapeutics…

SpringWorks Therapeutics (SWTX) announced that the first patient has been dosed in a Phase 1b clinical trial evaluating SpringWorks Therapeutics' investigational gamma secretase inhibitor, nirogacestat, in combination with GlaxoSmithKline's (GSK) investigational anti-B-cell maturation antigen antibody-drug conjugate, belantamab mafodotin, in patients with relapsed or refractory multiple myeloma. The nirogacestat and belantamab mafodotin combination is being evaluated as a sub-study in GSK's ongoing DREAMM-5 platform trial. The Phase 1b combination trial is being advanced pursuant to a global clinical trial collaboration agreement that SpringWorks and GSK entered into in June 2019. Under the terms of the agreement, GSK is sponsoring and conducting the Phase 1b study to evaluate the safety, tolerability and preliminary efficacy of the combination, and is assuming all development costs associated with the study, other than expenses related to the manufacturing of nirogacestat and certain expenses related to intellectual property rights. SpringWorks and GlaxoSmithKline have formed a joint development committee to help manage and oversee the clinical study.

ShowHide Related Items >><<
SWTX SpringsWorks Therapeutics
$44.98 /

-3.53 (-7.28%)

GSK GlaxoSmithKline
$41.12 /

+0.18 (+0.44%)

SWTX SpringsWorks Therapeutics
$44.98 /

-3.53 (-7.28%)

06/02/20 Citi
Ayala Pharmaceuticals initiated with a Buy at Citi
05/05/20 Barclays
SpringsWorks Therapeutics initiated with an Overweight at Barclays
03/19/20 H.C. Wainwright
SpringsWorks Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
03/04/20
Fly Intel: Top five analyst downgrades
GSK GlaxoSmithKline
$41.12 /

+0.18 (+0.44%)

06/19/20 Barclays
Glaxo belantamab AdCom a surprise, supports cautious view, says Barclays
06/16/20 Roth Capital
Ideaya Biosciences price target raised to $23 from $12 at Roth Capital
05/14/20 UBS
GlaxoSmithKline price target raised to 1,920 GBp from 1,900 GBp at UBS
05/05/20 JPMorgan
GlaxoSmithKline price target lowered to 1,700 GBp from 1,750 GBp at JPMorgan
SWTX SpringsWorks Therapeutics
$44.98 /

-3.53 (-7.28%)

GSK GlaxoSmithKline
$41.12 /

+0.18 (+0.44%)

GSK GlaxoSmithKline
$41.12 /

+0.18 (+0.44%)

GSK GlaxoSmithKline
$41.12 /

+0.18 (+0.44%)

GSK GlaxoSmithKline
$41.12 /

+0.18 (+0.44%)

Conference/Events
Goldman Sachs to hold a virtual conference » 04:55
06/11/20
06/11
04:55
06/11/20
04:55
CERN

Cerner

$71.85 /

-0.03 (-0.04%)

, INCY

Incyte

$93.07 /

+ (+0.00%)

, ALC

Alcon

$61.28 /

-0.22 (-0.36%)

, MDT

Medtronic

$97.57 /

-1.44 (-1.45%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, FMS

Fresenius Medical

$43.62 /

+0.18 (+0.41%)

, IVBXF

Innovent Biologics

$0.00 /

+ (+0.00%)

, QURE

uniQure

$63.09 /

-0.08 (-0.13%)

, SWTX

SpringsWorks Therapeutics

$45.20 /

+2.21 (+5.14%)

41st Annual Global…

41st Annual Global Healthcare Virtual Conference will be held on June 9-11. Webcast Link

ShowHide Related Items >><<
SWTX SpringsWorks Therapeutics
$45.20 /

+2.21 (+5.14%)

RHHBY Roche
$0.00 /

+ (+0.00%)

QURE uniQure
$63.09 /

-0.08 (-0.13%)

MDT Medtronic
$97.57 /

-1.44 (-1.45%)

INCY Incyte
$93.07 /

+ (+0.00%)

FMS Fresenius Medical
$43.62 /

+0.18 (+0.41%)

CERN Cerner
$71.85 /

-0.03 (-0.04%)

ALC Alcon
$61.28 /

-0.22 (-0.36%)

CERN Cerner
$71.85 /

-0.03 (-0.04%)

06/10/20 Lake Street
OptimizeRx news strategically significant, broadens reach, says Lake Street
06/09/20 Piper Sandler
GAO reports validate Cerner contract with VA, says Piper Sandler
05/01/20 Truist
Cerner downgraded to Hold from Buy at SunTrust
05/01/20 Truist
Cerner downgraded to Hold from Buy at SunTrust
INCY Incyte
$93.07 /

+ (+0.00%)

06/04/20 Argus
Incyte price target raised to $124 from $92 at Argus
05/26/20 Goldman Sachs
Incyte downgraded to Buy from Conviction Buy at Goldman Sachs
05/19/20 Cantor Fitzgerald
Incyte price target raised to $100 from $83 at Cantor Fitzgerald
05/06/20 Piper Sandler
Incyte approval of Tabrecta came soon than expected, says Piper Sandler
ALC Alcon
$61.28 /

-0.22 (-0.36%)

06/05/20 UBS
UBS backs Buy on Alcon after Cooper results
05/21/20 JPMorgan
Alcon price target lowered to CHF 55 from CHF 58 at JPMorgan
05/14/20 UBS
Alcon price target raised to CHF 65 from CHF 60 at UBS
05/14/20 Stephens
Alcon upgraded to Overweight on quicker bounce back potential at Stephens
MDT Medtronic
$97.57 /

-1.44 (-1.45%)

05/26/20 Truist
Medtronic price target lowered to $105 from $130 at SunTrust
05/21/20 Piper Sandler
Medtronic price target lowered to $120 from $135 at Piper Sandler
05/21/20 Piper Sandler
Medtronic robot delay positive for Intuitive Surgical, says Piper Sandler
05/14/20 DZ Bank
Medtronic downgraded to Hold from Buy at DZ Bank
RHHBY Roche
$0.00 /

+ (+0.00%)

06/10/20 Truist
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/10/20 Morgan Stanley
Morgan Stanley calls Merck bladder cancer failure 'marginal perception negative'
05/15/20 Barclays
Roche price target raised to CHF 395 from CHF 385 at Barclays
05/14/20 Mizuho
Arcus Biosciences price target raised to $40 from $22 at Mizuho
FMS Fresenius Medical
$43.62 /

+0.18 (+0.41%)

06/01/20 Barclays
Fresenius Medical price target raised to EUR 88 from EUR 81 at Barclays
05/20/20
Fly Intel: Top five analyst upgrades
05/20/20 Morgan Stanley
Fresenius Medical upgraded to Equal Weight from Underweight at Morgan Stanley
05/19/20 JPMorgan
Fresenius Medical price target lowered to EUR 84.20 from EUR 90.80 at JPMorgan
IVBXF Innovent Biologics
$0.00 /

+ (+0.00%)

QURE uniQure
$63.09 /

-0.08 (-0.13%)

03/26/20 Piper Sandler
uniQure trial delay 'comes as no surprise,' says Piper Sandler
01/23/20 Cantor Fitzgerald
Cantor sees further upside in uniQure, calls 'highly attractive' buyout candiate
12/10/19 Mizuho
uniQure price target raised to $90 from $67 at Mizuho
12/09/19 Piper Sandler
Piper says uniQure solidified 'front runner' position in Hemophilia B at ASH
SWTX SpringsWorks Therapeutics
$45.20 /

+2.21 (+5.14%)

06/02/20 Citi
Ayala Pharmaceuticals initiated with a Buy at Citi
05/05/20 Barclays
SpringsWorks Therapeutics initiated with an Overweight at Barclays
03/19/20 H.C. Wainwright
SpringsWorks Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
03/04/20
Fly Intel: Top five analyst downgrades
SWTX SpringsWorks Therapeutics
$45.20 /

+2.21 (+5.14%)

RHHBY Roche
$0.00 /

+ (+0.00%)

QURE uniQure
$63.09 /

-0.08 (-0.13%)

MDT Medtronic
$97.57 /

-1.44 (-1.45%)

INCY Incyte
$93.07 /

+ (+0.00%)

FMS Fresenius Medical
$43.62 /

+0.18 (+0.41%)

CERN Cerner
$71.85 /

-0.03 (-0.04%)

ALC Alcon
$61.28 /

-0.22 (-0.36%)

RHHBY Roche
$0.00 /

+ (+0.00%)

MDT Medtronic
$97.57 /

-1.44 (-1.45%)

CERN Cerner
$71.85 /

-0.03 (-0.04%)

RHHBY Roche
$0.00 /

+ (+0.00%)

QURE uniQure
$63.09 /

-0.08 (-0.13%)

MDT Medtronic
$97.57 /

-1.44 (-1.45%)

INCY Incyte
$93.07 /

+ (+0.00%)

CERN Cerner
$71.85 /

-0.03 (-0.04%)

QURE uniQure
$63.09 /

-0.08 (-0.13%)

MDT Medtronic
$97.57 /

-1.44 (-1.45%)

INCY Incyte
$93.07 /

+ (+0.00%)

CERN Cerner
$71.85 /

-0.03 (-0.04%)

Conference/Events
Goldman Sachs to hold a virtual conference » 04:55
06/10/20
06/10
04:55
06/10/20
04:55
CERN

Cerner

$71.88 /

-1.95 (-2.64%)

, INCY

Incyte

$93.27 /

-1.3 (-1.37%)

, ALC

Alcon

$61.50 /

-1.465 (-2.33%)

, MDT

Medtronic

$99.01 /

-2.17 (-2.14%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, FMS

Fresenius Medical

$43.44 /

-0.25 (-0.57%)

, IVBXF

Innovent Biologics

$0.00 /

+ (+0.00%)

, QURE

uniQure

$63.17 /

+1.67 (+2.72%)

, SWTX

SpringsWorks Therapeutics

$42.99 /

+3.83 (+9.78%)

41st Annual Global…

41st Annual Global Healthcare Virtual Conference will be held on June 9-11. Webcast Link

ShowHide Related Items >><<
SWTX SpringsWorks Therapeutics
$42.99 /

+3.83 (+9.78%)

RHHBY Roche
$0.00 /

+ (+0.00%)

QURE uniQure
$63.17 /

+1.67 (+2.72%)

MDT Medtronic
$99.01 /

-2.17 (-2.14%)

INCY Incyte
$93.27 /

-1.3 (-1.37%)

FMS Fresenius Medical
$43.44 /

-0.25 (-0.57%)

CERN Cerner
$71.88 /

-1.95 (-2.64%)

ALC Alcon
$61.50 /

-1.465 (-2.33%)

CERN Cerner
$71.88 /

-1.95 (-2.64%)

06/09/20 Piper Sandler
GAO reports validate Cerner contract with VA, says Piper Sandler
05/01/20 Truist
Cerner downgraded to Hold from Buy at SunTrust
05/01/20 Truist
Cerner downgraded to Hold from Buy at SunTrust
04/22/20
Fly Intel: Top five analyst upgrades
INCY Incyte
$93.27 /

-1.3 (-1.37%)

06/04/20 Argus
Incyte price target raised to $124 from $92 at Argus
05/26/20 Goldman Sachs
Incyte downgraded to Buy from Conviction Buy at Goldman Sachs
05/19/20 Cantor Fitzgerald
Incyte price target raised to $100 from $83 at Cantor Fitzgerald
05/06/20 Piper Sandler
Incyte approval of Tabrecta came soon than expected, says Piper Sandler
ALC Alcon
$61.50 /

-1.465 (-2.33%)

06/05/20 UBS
UBS backs Buy on Alcon after Cooper results
05/21/20 JPMorgan
Alcon price target lowered to CHF 55 from CHF 58 at JPMorgan
05/14/20 UBS
Alcon price target raised to CHF 65 from CHF 60 at UBS
05/14/20 Stephens
Alcon upgraded to Overweight on quicker bounce back potential at Stephens
MDT Medtronic
$99.01 /

-2.17 (-2.14%)

05/26/20 Truist
Medtronic price target lowered to $105 from $130 at SunTrust
05/21/20 Piper Sandler
Medtronic price target lowered to $120 from $135 at Piper Sandler
05/21/20 Piper Sandler
Medtronic robot delay positive for Intuitive Surgical, says Piper Sandler
05/14/20 DZ Bank
Medtronic downgraded to Hold from Buy at DZ Bank
RHHBY Roche
$0.00 /

+ (+0.00%)

05/15/20 Barclays
Roche price target raised to CHF 395 from CHF 385 at Barclays
05/14/20 Mizuho
Arcus Biosciences price target raised to $40 from $22 at Mizuho
05/13/20 Wolfe Research
Roche upgraded to Outperform from Peer Perform at Wolfe Research
05/13/20 Wolfe Research
Roche upgraded to Outperform from Peer Perform at Wolfe Research
FMS Fresenius Medical
$43.44 /

-0.25 (-0.57%)

06/01/20 Barclays
Fresenius Medical price target raised to EUR 88 from EUR 81 at Barclays
05/20/20
Fly Intel: Top five analyst upgrades
05/20/20 Morgan Stanley
Fresenius Medical upgraded to Equal Weight from Underweight at Morgan Stanley
05/19/20 JPMorgan
Fresenius Medical price target lowered to EUR 84.20 from EUR 90.80 at JPMorgan
IVBXF Innovent Biologics
$0.00 /

+ (+0.00%)

QURE uniQure
$63.17 /

+1.67 (+2.72%)

03/26/20 Piper Sandler
uniQure trial delay 'comes as no surprise,' says Piper Sandler
01/23/20 Cantor Fitzgerald
Cantor sees further upside in uniQure, calls 'highly attractive' buyout candiate
12/10/19 Mizuho
uniQure price target raised to $90 from $67 at Mizuho
12/09/19 Piper Sandler
Piper says uniQure solidified 'front runner' position in Hemophilia B at ASH
SWTX SpringsWorks Therapeutics
$42.99 /

+3.83 (+9.78%)

06/02/20 Citi
Ayala Pharmaceuticals initiated with a Buy at Citi
05/05/20 Barclays
SpringsWorks Therapeutics initiated with an Overweight at Barclays
03/19/20 H.C. Wainwright
SpringsWorks Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
03/04/20
Fly Intel: Top five analyst downgrades
SWTX SpringsWorks Therapeutics
$42.99 /

+3.83 (+9.78%)

RHHBY Roche
$0.00 /

+ (+0.00%)

QURE uniQure
$63.17 /

+1.67 (+2.72%)

MDT Medtronic
$99.01 /

-2.17 (-2.14%)

INCY Incyte
$93.27 /

-1.3 (-1.37%)

FMS Fresenius Medical
$43.44 /

-0.25 (-0.57%)

CERN Cerner
$71.88 /

-1.95 (-2.64%)

ALC Alcon
$61.50 /

-1.465 (-2.33%)

RHHBY Roche
$0.00 /

+ (+0.00%)

MDT Medtronic
$99.01 /

-2.17 (-2.14%)

CERN Cerner
$71.88 /

-1.95 (-2.64%)

RHHBY Roche
$0.00 /

+ (+0.00%)

QURE uniQure
$63.17 /

+1.67 (+2.72%)

MDT Medtronic
$99.01 /

-2.17 (-2.14%)

INCY Incyte
$93.27 /

-1.3 (-1.37%)

CERN Cerner
$71.88 /

-1.95 (-2.64%)

QURE uniQure
$63.17 /

+1.67 (+2.72%)

MDT Medtronic
$99.01 /

-2.17 (-2.14%)

INCY Incyte
$93.27 /

-1.3 (-1.37%)

CERN Cerner
$71.88 /

-1.95 (-2.64%)

Conference/Events
Goldman Sachs to hold a virtual conference » 08:49
06/09/20
06/09
08:49
06/09/20
08:49
CERN

Cerner

$73.83 /

+0.8 (+1.10%)

, INCY

Incyte

$94.57 /

+1.13 (+1.21%)

, ALC

Alcon

$62.97 /

-0.075 (-0.12%)

, MDT

Medtronic

$101.18 /

-0.85 (-0.83%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, FMS

Fresenius Medical

$43.69 /

-0.29 (-0.66%)

, IVBXF

Innovent Biologics

$0.00 /

+ (+0.00%)

, QURE

uniQure

$61.50 /

+2.65 (+4.50%)

, SWTX

SpringsWorks Therapeutics

$39.16 /

+2.09 (+5.64%)

41st Annual Global…

41st Annual Global Healthcare Virtual Conference will be held on June 9-11. Webcast Link

ShowHide Related Items >><<
SWTX SpringsWorks Therapeutics
$39.16 /

+2.09 (+5.64%)

RHHBY Roche
$0.00 /

+ (+0.00%)

QURE uniQure
$61.50 /

+2.65 (+4.50%)

MDT Medtronic
$101.18 /

-0.85 (-0.83%)

INCY Incyte
$94.57 /

+1.13 (+1.21%)

FMS Fresenius Medical
$43.69 /

-0.29 (-0.66%)

CERN Cerner
$73.83 /

+0.8 (+1.10%)

ALC Alcon
$62.97 /

-0.075 (-0.12%)

CERN Cerner
$73.83 /

+0.8 (+1.10%)

05/01/20 Truist
Cerner downgraded to Hold from Buy at SunTrust
05/01/20 Truist
Cerner downgraded to Hold from Buy at SunTrust
04/22/20
Fly Intel: Top five analyst upgrades
04/22/20 Jefferies
Cerner upgraded to Buy with $90 price target at Jefferies
INCY Incyte
$94.57 /

+1.13 (+1.21%)

06/04/20 Argus
Incyte price target raised to $124 from $92 at Argus
05/26/20 Goldman Sachs
Incyte downgraded to Buy from Conviction Buy at Goldman Sachs
05/19/20 Cantor Fitzgerald
Incyte price target raised to $100 from $83 at Cantor Fitzgerald
05/06/20 Piper Sandler
Incyte approval of Tabrecta came soon than expected, says Piper Sandler
ALC Alcon
$62.97 /

-0.075 (-0.12%)

06/05/20 UBS
UBS backs Buy on Alcon after Cooper results
05/21/20 JPMorgan
Alcon price target lowered to CHF 55 from CHF 58 at JPMorgan
05/14/20 UBS
Alcon price target raised to CHF 65 from CHF 60 at UBS
05/14/20 Stephens
Alcon upgraded to Overweight on quicker bounce back potential at Stephens
MDT Medtronic
$101.18 /

-0.85 (-0.83%)

05/26/20 Truist
Medtronic price target lowered to $105 from $130 at SunTrust
05/21/20 Piper Sandler
Medtronic price target lowered to $120 from $135 at Piper Sandler
05/21/20 Piper Sandler
Medtronic robot delay positive for Intuitive Surgical, says Piper Sandler
05/14/20 DZ Bank
Medtronic downgraded to Hold from Buy at DZ Bank
RHHBY Roche
$0.00 /

+ (+0.00%)

05/15/20 Barclays
Roche price target raised to CHF 395 from CHF 385 at Barclays
05/14/20 Mizuho
Arcus Biosciences price target raised to $40 from $22 at Mizuho
05/13/20 Wolfe Research
Roche upgraded to Outperform from Peer Perform at Wolfe Research
05/13/20 Wolfe Research
Roche upgraded to Outperform from Peer Perform at Wolfe Research
FMS Fresenius Medical
$43.69 /

-0.29 (-0.66%)

06/01/20 Barclays
Fresenius Medical price target raised to EUR 88 from EUR 81 at Barclays
05/20/20
Fly Intel: Top five analyst upgrades
05/20/20 Morgan Stanley
Fresenius Medical upgraded to Equal Weight from Underweight at Morgan Stanley
05/19/20 JPMorgan
Fresenius Medical price target lowered to EUR 84.20 from EUR 90.80 at JPMorgan
IVBXF Innovent Biologics
$0.00 /

+ (+0.00%)

QURE uniQure
$61.50 /

+2.65 (+4.50%)

03/26/20 Piper Sandler
uniQure trial delay 'comes as no surprise,' says Piper Sandler
01/23/20 Cantor Fitzgerald
Cantor sees further upside in uniQure, calls 'highly attractive' buyout candiate
12/10/19 Mizuho
uniQure price target raised to $90 from $67 at Mizuho
12/09/19 Piper Sandler
Piper says uniQure solidified 'front runner' position in Hemophilia B at ASH
SWTX SpringsWorks Therapeutics
$39.16 /

+2.09 (+5.64%)

06/02/20 Citi
Ayala Pharmaceuticals initiated with a Buy at Citi
05/05/20 Barclays
SpringsWorks Therapeutics initiated with an Overweight at Barclays
03/19/20 H.C. Wainwright
SpringsWorks Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
03/04/20
Fly Intel: Top five analyst downgrades
SWTX SpringsWorks Therapeutics
$39.16 /

+2.09 (+5.64%)

RHHBY Roche
$0.00 /

+ (+0.00%)

QURE uniQure
$61.50 /

+2.65 (+4.50%)

MDT Medtronic
$101.18 /

-0.85 (-0.83%)

INCY Incyte
$94.57 /

+1.13 (+1.21%)

FMS Fresenius Medical
$43.69 /

-0.29 (-0.66%)

CERN Cerner
$73.83 /

+0.8 (+1.10%)

ALC Alcon
$62.97 /

-0.075 (-0.12%)

RHHBY Roche
$0.00 /

+ (+0.00%)

MDT Medtronic
$101.18 /

-0.85 (-0.83%)

CERN Cerner
$73.83 /

+0.8 (+1.10%)

RHHBY Roche
$0.00 /

+ (+0.00%)

QURE uniQure
$61.50 /

+2.65 (+4.50%)

MDT Medtronic
$101.18 /

-0.85 (-0.83%)

INCY Incyte
$94.57 /

+1.13 (+1.21%)

CERN Cerner
$73.83 /

+0.8 (+1.10%)

QURE uniQure
$61.50 /

+2.65 (+4.50%)

MDT Medtronic
$101.18 /

-0.85 (-0.83%)

INCY Incyte
$94.57 /

+1.13 (+1.21%)

CERN Cerner
$73.83 /

+0.8 (+1.10%)

Initiation
Ayala Pharmaceuticals initiated with a Buy at Citi » 06:15
06/02/20
06/02
06:15
06/02/20
06:15
AYLA

Ayala Pharmaceuticals

$15.30 /

+0.24 (+1.59%)

, SWTX

SpringsWorks Therapeutics

$39.06 /

+0.835 (+2.18%)

Citi analyst Joel Beatty…

Citi analyst Joel Beatty initiated coverage of Ayala Pharmaceuticals (AYLA) with a Buy rating and $25 price target. The analyst views AL101 as a "pipeline in a product" and believes AL102 is a potentially "fast follower" to SpringsWorks Therapeutics' (SWTX) Nirogacestat.

ShowHide Related Items >><<
SWTX SpringsWorks Therapeutics
$39.06 /

+0.835 (+2.18%)

AYLA Ayala Pharmaceuticals
$15.30 /

+0.24 (+1.59%)

SWTX SpringsWorks Therapeutics
$39.06 /

+0.835 (+2.18%)

05/05/20 Barclays
SpringsWorks Therapeutics initiated with an Overweight at Barclays
03/19/20 H.C. Wainwright
SpringsWorks Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
03/04/20
Fly Intel: Top five analyst downgrades
03/04/20 H.C. Wainwright
SpringsWorks Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
SWTX SpringsWorks Therapeutics
$39.06 /

+0.835 (+2.18%)

AYLA Ayala Pharmaceuticals
$15.30 /

+0.24 (+1.59%)

Hot Stocks
SpringsWorks Therapeutics says COVID-19 has had 'relatively modest impact' » 07:32
05/12/20
05/12
07:32
05/12/20
07:32
SWTX

SpringsWorks Therapeutics

$33.11 /

+1.215 (+3.81%)

To date, the COVID-19…

To date, the COVID-19 pandemic has had a relatively modest impact on SpringWorks' business operations, in particular on SpringWorks' clinical trial programs, and the company is undertaking considerable efforts to mitigate the various challenges presented by this crisis.

ShowHide Related Items >><<
SWTX SpringsWorks Therapeutics
$33.11 /

+1.215 (+3.81%)

SWTX SpringsWorks Therapeutics
$33.11 /

+1.215 (+3.81%)

05/05/20 Barclays
SpringsWorks Therapeutics initiated with an Overweight at Barclays
03/19/20 H.C. Wainwright
SpringsWorks Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
03/04/20
Fly Intel: Top five analyst downgrades
03/04/20 H.C. Wainwright
SpringsWorks Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
SWTX SpringsWorks Therapeutics
$33.11 /

+1.215 (+3.81%)

Earnings
SpringsWorks Therapeutics reports Q1 EPS (37c), consensus (37c) » 07:31
05/12/20
05/12
07:31
05/12/20
07:31
SWTX

SpringsWorks Therapeutics

$33.11 /

+1.215 (+3.81%)

"We are pleased with…

"We are pleased with our execution in the first quarter of 2020, which included building upon our existing intellectual property portfolio by extending the patent protection for our lead product candidate, nirogacestat, to 2039, while continuing to advance our diversified pipeline of targeted oncology programs," said Saqib Islam, Chief Executive Officer of SpringWorks. "Our focus for the remainder of the year continues to be on enrolling patients in our ongoing clinical trials, advancing nirogacestat as a cornerstone of BCMA combination therapy for patients with multiple myeloma, and further expanding our portfolio through additional business development activities."

ShowHide Related Items >><<
SWTX SpringsWorks Therapeutics
$33.11 /

+1.215 (+3.81%)

SWTX SpringsWorks Therapeutics
$33.11 /

+1.215 (+3.81%)

05/05/20 Barclays
SpringsWorks Therapeutics initiated with an Overweight at Barclays
03/19/20 H.C. Wainwright
SpringsWorks Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
03/04/20
Fly Intel: Top five analyst downgrades
03/04/20 H.C. Wainwright
SpringsWorks Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
SWTX SpringsWorks Therapeutics
$33.11 /

+1.215 (+3.81%)

Over a quarter ago
Initiation
SpringsWorks Therapeutics initiated with an Overweight at Barclays » 06:28
05/05/20
05/05
06:28
05/05/20
06:28
SWTX

SpringsWorks Therapeutics

$29.84 /

-0.5 (-1.65%)

Barclays analyst Peter…

Barclays analyst Peter Lawson initiated coverage of SpringsWorks Therapeutics with an Overweight rating and $48 price target. he analyst expanded coverage with six additional SMID cap oncology stocks in the U.S. Small & Mid Cap Biotechnology sector, where he has a Positive view.

ShowHide Related Items >><<
SWTX SpringsWorks Therapeutics
$29.84 /

-0.5 (-1.65%)

03/19/20 H.C. Wainwright
SpringsWorks Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
03/04/20
Fly Intel: Top five analyst downgrades
03/04/20 H.C. Wainwright
SpringsWorks Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
01/21/20 H.C. Wainwright
SpringsWorks price target raised to $40 from $34 at H.C. Wainwright

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.